Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.749083
Abstract: Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used off-label for the treatment of many other malignancies.… read more here.
Keywords: treatment malignancies; treatment; efficacy; apatinib treatment ... See more keywords